Yu Onozaki;Michael A. Rossi;Yasuhiro Goto;Takashi Mita;Toshihiro Sakamoto;Philip E. Sanderson;Hidetomo Furuyama;Jiabing Wang;Mark E. Layton;Nobuhiko Kawanishi;Yoshio Ogino
发明人:
Hidetomo Furuyama,Yasuhiro Goto,Nobuhiko Kawanishi,Mark E. Layton,Takashi Mita,Yoshio Ogino,Yu Onozaki,Michael A. Rossi,Toshihiro Sakamoto,Philip E. Sanderson,Jiabing Wang
申请号：
US12995892
公开号：
US08536193B2
申请日:
2009.05.27
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.
